FDA Delays Decision on Frontline Atezolizumab for NSCLC

September 6, 2018 – The FDA has extended the review period for a supplemental biologics license application (sBLA) for atezolizumab for use in combination with bevacizumab, carboplatin, and paclitaxel (ABCP) for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC). Roche (Genentech), the manufacturer of the PD-L1 inhibitor atezolizumab, reported in a press release that the extension will allow ample time … (leggi tutto)